NCT02444338已完成不适用
Randomised Investigation of the MitraClip Device in Heart Failure: 2nd Trial in Patients With Clinically Significant Functional Mitral Regurgitation
University Medical Center Goettingen55 个研究点 分布在 9 个国家目标入组 505 人开始时间: 2015年3月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 505
- 试验地点
- 55
- 主要终点
- Rate of total (first and recurrent) HF hospitalizations within 24 months
研究概览
简要总结
To study the safety and effectiveness of the MitraClip System in the treatment of clinically significant functional mitral regurgitation in patients with New York Heart Association (NYHA) Functional Class II to Class IV chronic heart failure.
详细描述
The trial is designed to provide additional evidence regarding appropriate recommendations for use of the MitraClip System for patients with chronic heart failure and clinically significant functional mitral regurgitation. Additionally, the trial will collect evidence regarding health economics of the MitraClip System for use in this patient population.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
盲法说明
PROBE
- outcome assessment: blinded
- patient & investigator: open
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Clinically significant functional mitral regurgitation (moderate-to-severe or severe MR) as defined by European Association of Echocardiography, within 90 days prior to randomization and confirmed by the Echocardiography Core Laboratory Note: The TTE must be obtained after the subject has been stabilized on optimal therapy and has undergone revascularization and/or CRT, as appropriate
- •Assessed by the investigator to be on optimal standard of care therapy for heart failure, according to current ESC/HFA guidelines with no dose changes of heart failure drugs (with the exception of diuretics) during the last 2 weeks immediately prior to randomization.
- •Symptomatic with documented New York Heart Association Class II, III or IV heart failure, despite optimal standard of care therapy, within 30 days preceding randomization
- •Minimum of one documented hospitalization (acute care admission or emergency room visit) for heart failure within 12 months preceding randomization OR values of 300 pg/mL for BNP or 1000 pg/mL for NT-proBNP after optimal medical and/or device management within 90 days preceding randomization Note: BNP or NT-proBNP must be obtained after the subject has been stabilized on optimal therapy and has undergone revascularization and/or CRT, as appropriate
- •Ambulatory patient with symptomatic congestive heart failure (CHF) in NYHA functional class II to IV (despite optimal standard of care therapy as assessed within 30 days preceding randomization) and with LVEF 20% to 50%. Note: LVEF needs to be determined by one of the following methods: transthoracic echocardiography (TTE), contrast ventriculography, gated blood pool scan, cardiac magnetic resonance) within 90 days prior to randomization
- •Patient is ambulatory and able to perform a 6MWT with the only limiting factor(s) being due to cardiovascular fitness
排除标准
- •Mitral regurgitation is primarily due to degenerative disease of the mitral valve apparatus (Degenerative MR) as determined by transesophageal echocardiography (TEE).
- •Status 1 heart transplant or prior orthotropic heart transplantation.
- •Introduction of a new heart failure drug class within the last 2 weeks prior to randomization.
- •Evidence of acute coronary syndrome, transient ischemic attack or stroke within 90 days prior to randomization. Note:Acute coronary syndrome (ACS) is defined as an ACS that requires an intervention. Increased troponin without acute symptoms and chest pain is not defined as ACS.
- •Any percutaneous cardiovascular intervention, carotid surgery, cardiovascular surgery, or atrial fibrillation ablation within 90 days prior to randomization.
- •Therapy with or without cardioverter-defibrillator (CRT or CRT-D), or Implantable Cardioverter Defibrillator (ICD)) within 90 day prior to randomization, or revision of any implanted rhythm management device within 90 days prior to randomization.
- •Need for any cardiovascular surgery.
- •Mitral valve surgery is considered the preferred therapeutic option for the subject
- •Renal replacement therapy
- •6-Minute Walk Test (6MWT) distance > 475 meters
- •Mitral Valve Area (MVA) by planimetry < 4.0 cm2; if MVA by planimetry is not measurable, pressure half-time measurement is acceptable; MVA must be confirmed by the Echocardiography Core Laboratory
结局指标
主要结局
Rate of total (first and recurrent) HF hospitalizations within 24 months
时间窗: 24 months
Rate of total (first and recurrent) HF hospitalizations within 24 months
Composite rate of recurrent heart failure hospitalizations and cardiovascular (CV) death within 24 months
时间窗: 24 months
Composite rate of recurrent heart failure hospitalizations and cardiovascular (CV) death within 24 months
Change in quality of life (i.e. overall KCCQ score) from baseline to 12 months
时间窗: 12 months
Change in quality of life (i.e. overall KCCQ score) from baseline to 12 months
次要结局
- Rate of total (first and recurrent) hospitalizations for any cause within 24 months(24 months)
- Percentage of patients in NYHA function class I/II at 12 months(12 months)
- Change in 6 Minute Walking Test distance from baseline to 12 months(from baseline to 12 months)
- Percentage of patients with mitral regurgitation grade of 2+ or lower at 12 months as assessed by the Echocardiography Core Laboratory(at 12 months)
- All-cause mortality during all available follow-up(during all available follow-up)
研究者
Karsten Gavenis
on behalf of Principle Investigator Prof. Wolfgang Schillinger and Prof. Stefan D. Anker
University Medical Center Goettingen
研究点 (55)
Loading locations...
相似试验
撤回
不适用
The RESHAPE-HF1-FU StudyMitral Valve InsufficiencyNCT02444286Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH
终止
不适用
Transcatheter Mitral Valve Repair for the Treatment of Mitral Valve Regurgitation In Heart Failure (The EVOLVE-MR Trial)Ventricular Remodeling, LeftNCT03891823Montreal Heart Institute9
Unknown
不适用
MitraClip® and Hemodynamic Effects of Relevant Iatrogenic Atrial Septum Defect ClosureMitral Valve InsufficiencyHeart Septal Defects, AtrialNCT03024268Heart Center Leipzig - University Hospital80
招募中
不适用
MitraClip® RegistryMitral RegurgitationNCT02033811Klinik für Kardiologie, Pneumologie und Angiologie200
进行中（未招募）
不适用
MitraClip REPAIR MR StudyMitral Valve RegurgitationNCT04198870Abbott Medical Devices500